Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect (2024)

What is Open Access?

Open Access is an initiative that aims to make scientific research freely available to all. To date our community has made over 100 million downloads. It’s based on principles of collaboration, unobstructed discovery, and, most importantly, scientific progression. As PhD students, we found it difficult to access the research we needed, so we decided to create a new Open Access publisher that levels the playing field for scientists across the world. How? By making research easy to access, and puts the academic needs of the researchers before the business interests of publishers.

Our Authors and Editors

We are a community of more than 103,000 authors and editors from 3,291 institutions spanning 160 countries, including Nobel Prize winners and some of the world’s most-cited researchers. Publishing on IntechOpen allows authors to earn citations and find new collaborators, meaning more people see your work not only from your own field of study, but from other related fields too.

Content Alerts

Brief introduction to this section that descibes Open Access especially from an IntechOpen perspective

How it Works Manage preferences

Contact

Want to get in touch? Contact our London head office or media team here

Careers

Our team is growing all the time, so we’re always on the lookout for smart people who want to help us reshape the world of scientific publishing.

Home > Books > Smart Drug Delivery Systems - Futuristic Window in Cancer Therapy [Working Title]

Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect (2)Open access peer-reviewed chapter - ONLINE FIRST

Written By

Shayeri Biswas and Sankarprasad Bhuniya

Reviewed: 20 May 2024 Published: 08 July 2024

DOI: 10.5772/intechopen.115104

Chapter metrics overview

View Full Metrics

Abstract

Since the prehistorical period, cancer has been a pervasive affliction in the human body, representing one of the most formidable challenges to human health and well-being. Its insidious presence in the human body commands the highest mortality rate among those who succumb to its grasp. Epigenetic factors often play a critical role as the primary caretakers orchestrating the transformation from an innocuous, rudimentary stage to the formidable and often fatal metastasis phase. In the battle against this lethal illness, the concept of theranostics was embraced in the early twenty-first century, combining both treatment and diagnostic techniques. This prompt data on treatment methods could pave the way for the advancement of tailored medicine, potentially curbing medication misuse as well. The use of fluorescence as a partially invasive method has been adapted for diagnostic purposes in the field of intelligent medicine. Within this approach, the overexpression of unique elements (ROS, thiols, enzymes, proteins, etc.) within cancer cells facilitates the cleavage of the theranostic agent, resulting in the immediate release of drugs exclusively in cancer cells. This approach rapidly offers temporal data on the activation of therapies and their effects at the subcellular level in animal models, as demonstrated through in situ biopsies.

Keywords

  • endogenous stimulators
  • theranostics
  • prodrug
  • fluorescence
  • cancer

Author Information

Show +

  • Shayeri Biswas

    • Centre for Interdisciplinary Sciences, JIS Institute of Advanced Studies and Research Arch Waterfront, Kolkata, India
  • Sankarprasad Bhuniya*

    • Centre for Interdisciplinary Sciences, JIS Institute of Advanced Studies and Research Arch Waterfront, Kolkata, India

*Address all correspondence to: spbhuniya@jisiasr.org

1. Introduction

Cancer represents a potentially life-threatening condition within human society, with its various types categorized based on their origin and location [1]. Alterations in the genes responsible for cellular signaling, particularly the malfunctioning of protein kinases, can lead to the growth of cancer [2]. The unveiling of the human genome sequence has spurred the development of novel treatment protocols for this ailment.

In 2004, the U.S. Food and Drug Administration (FDA) promoted the exploration of innovative products for cancer treatment, specifically emphasizing personalized medicine to mitigate drug misuse and encourage targeted therapy. The pharmaceutical industry views the “Trojan horse” approach, in conjunction with therapeutic and diagnostic tools, as a potential solution for precise treatment. The term “theranostic” was initially coined by John Funkhouser, the Chief Executive Officer of PharmaNetics, in 1998, and has since become a widely searched keyword in cancer research.

Parallel advancements in chemistry, biotechnology, nanotechnology, pharmacy, medicine, and imaging have led to the continual development and assessment of theranostic nanomedicine and its clinical significance in recent years [3]. Engineered nanoparticles and devices have been crafted to meet the current demands for personalized treatment. Research in the realm of theranostic tools for cancer treatment has resulted in the development of various anticancer drugs and carriers, such as polymers, liposomes, and diverse nanoparticles.

In the initial stages of theranostic nanomedicine development before 2005, therapeutic and diagnostic tools were incorporated into polymer vehicles that passively entered the target site due to the enhanced permeability and retention (EPR) effect. Subsequently, theranostic nanomedicines were devised with specific ligands capable of targeting particular cancer types based on their genetic signatures or the expression of specific proteins in tumor cells. This approach capitalizes inherent variance between normal and cancer cells to enhance cancer cell-specific uptake. The technologies behind targeted theranostic nanocarriers have exhibited desirable improved properties at the treatment site, localizing specifically to affected areas, providing targeted therapeutic release, and enabling noninvasive monitoring with diagnostic tools [4].

While targeted therapy has demonstrated effective therapeutic efficacy, various imaging modalities, including magnetic resonance imaging (MRI), positron emission tomography (PET), ultrasound, fluorescence, and computed tomography, have shed light on the underlying disease mechanisms and facilitated assessment in pre-and post-treatment stages [5, 6, 7, 8, 9].

Newly developed materials, including upconversion nanoparticles, graphene-based nanodevices, and other theranostic prodrugs, have been introduced as innovative solutions to address various forms of sporadically mutated cancer. Contrarily, the primary obstacle lies in surpassing the limitations of imaging for seamless in vivo visualization. Ultimately, the overall aim of nanomedicine is to fulfill the objective of providing personalized medicine [10].

Considerable efforts have been dedicated to the creation of theranostic tools, although most of these tools rely on nanoparticle technology. Regrettably, none of the existing nanoparticles are capable of offering real-time insights into the process of drug release and its activation. Currently, advanced techniques, such as small molecular optical-modulated theranostics, appear to be resolving this issue and instilling confidence in tailoring suitable treatments for individual patients. These newer methodologies, particularly those involving ROS-activatable systems, enzymes, and similar agents, facilitate the precise delivery of therapeutic agents to specific tumor regions [11]. In this approach, chemotherapeutic agents are linked to a tumor-guiding group via a self-immolative linker, allowing them to enter tumor tissues and activate within. The structural framework of these systems is relatively straightforward, compact, reproducible, and biocompatible, enabling easy modifications to achieve the desired effectiveness in chemotherapy and displaying enhanced cellular uptake, making them preferred candidates for chemotherapy compared to nano-theranostics. Discussions within the review encompass the causes of cancer formation and their variant, early drug development and delivery strategies, the design approaches of small conjugate-based theranostics, the underlying mechanisms of drug activation, and various imaging techniques used for precise cancer diagnosis. The review is structured to explore diagnostic methods and the mechanisms involved in activating theranostics at the tumor site.

Advertisem*nt

2. Cancer formation and their properties

Cancer is characterized by the fundamental anomaly of unregulated cell growth across various cell types. This irregularity is manifested through the modification of normal cellular signaling pathways, invasion into healthy cells and tissues, and eventual dissemination throughout the body, often in the form of metastasis.

Essentially, modifications in epigenetics profoundly influence the expression of genes, which serves as the inception of cancer [12]. Gene mutations are greatly impacted by changes in DNA, including modifications like DNA methylation and hydroxymethylation, as well as alterations in histone acetylation, histone methylation, and variations in small noncoding RNAs. Consequently, these changes give rise to unregulated cell division, ultimately resulting in the expansion of tumor cell population which originate from a single clone. Frequently, cancer-causing substances, including arsenic and its derivatives, asbestos, benzo(a)pyrene, polyaromatic, dimethylnitrosamine, nickel compounds, and others harm the DNA, leading to gene mutations. These altered genes foster the invasion of tumors and diminish the function of tumor suppressor genes [13]. Apart from the cancer-causing agents, tumor growth stimulants are also triggered during the initial phase of cancer prognosis through the activation of protein kinase C induced by phorbol ester [14]. Furthermore, epigenetic suppression entails an overabundance of methylation on the DNA repair protein O6-methylguanine DNA methyltransferase (MGMT), resulting in the deactivation of MGMT for DNA repair, a process frequently observed in cancerogenesis. Within cancer cells, micro-RNAs, a type of noncoding RNA comprising around twenty bases, bind to messenger RNAs, leading to their degradation or the inhibition of translation. This process significantly influences the growth and spread of numerous cancer types [15].

The unrestricted proliferation of cancer cells leads to numerous alterations in cellular communication, the cell cycle, cell adhesion, and the extracellular matrix. Typically, the growth pattern of normal cells is tightly regulated, with density-dependent inhibition restricting further cell growth, overseen by cell growth regulators. However, during the progression of cancer cells, the phenotype of extracellular growth factor receptors changes, and the density-dependent inhibition process becomes ineffective. Occasionally, cancer generates fresh growth factors to promote unregulated growth, a process known as autocrine growth stimulation, making it independent of the usual growth factors that regulate the growth of normal cells [16]. Consequently, cellular growth signaling varies in cancer cells, where the intracellular signaling pathway is disrupted by the deactivation of growth factor receptors or other critical proteins, such as Ras proteins or protein kinases [17].

The adhesion between cells and their attachment to the matrix is notably weaker in cancer cells. Within these cells, the primary adhesion function of E-cadherin in cell-matrix interactions is compromised, resulting in decreased activity. Receptors responsible for cell-cell attachment are downregulated, while those associated with cell motility are upregulated. Additionally, this process stimulates the activation or overexpression of surface metalloproteases, leading to the degradation of the extracellular matrix. This degradation facilitates the movement of cells with mesenchymal traits, which is crucial for metastasis. Also, increased secretion of collagenase has enhanced the capacity of carcinomas to break down and penetrate basal laminae, facilitating the invasion of underlying connective tissue. Moreover, the heightened expression of vascular endothelial growth factor receptors fosters the creation of fresh blood vessels.

Importantly, within tumor cells, the process of apoptosis, which typically serves as a tightly controlled mechanism for cell death in the development and sustenance of a normal cell population in mature organisms, is also disrupted. Anomalies in the apoptosis process are also a prominent characteristic of carcinogenesis. In certain types of cancer, the natural intrinsic apoptosis pathway is hindered by regulators like X-linked inhibitor of apoptosis protein (XIAP) and the B-cell lymphoma 2 family of proteins [18]. Similarly, the proteins FLIPL and FLIPS also impede alternative extrinsic pathways [19].

Numerous notable distinctions between cancer and normal cells contribute to their accelerated growth rates and enhanced migratory capabilities.

Advertisem*nt

3. Anticancer drugs and delivery

During the sixteenth-century, the pioneering physician Paracelsus was among the first to utilize medicine and minerals in the treatment of cancer. Up until 2020, the FDA had approved approximately 89 medications intended for the treatment of cancer [20]. These medications are categorized as alkylating agents, antimetabolites, anthracyclines, plant alkaloids, microtubule inhibitors or modulators, topoisomerase inhibitors, chromosome binding agents, and other antitumor treatments. These drugs exhibited anticancer effects by causing DNA fragmentation, inhibiting topoisomerase activity, and inducing apoptosis through different mechanistic pathways. In more than 90% of instances, chemotherapy is prescribed with the primary goal of providing palliative care, aiming to either stabilize the disease or enhance the patient’s quality of life. Regrettably, the limited rate of drug accumulation within cancer cells is insufficient to manage the rapid growth of tumors effectively. Therefore, combination therapy might be more effective in controlling the swift and proliferative cancer growth. Nonetheless, the intrinsic heterogeneous characteristics and hypoxic conditions significantly disrupt the effectiveness of anticancer drugs in chemotherapy. Even during advanced stages, various factors such as multidrug resistance, changes in drug activation mechanisms, detoxification, activation of cellular efflux, and delayed apoptosis further diminish the anticancer efficacy of chemotherapy [21]. The idea of drug delivery emerges as a means to expand the therapeutic window, which is presently limited. In general, micro/macro encapsulated particles, polymer-bound micro drug delivery systems, and prodrug-linked low molecular weight drug delivery systems are frequently utilized. Ligand-receptor interaction-based targeted delivery system is the key strategy behind the effective transport of chemotherapeutics agents to the cancerous region. Generally, integrin-binding RGD peptide, folic acid, monoclonal antibody, glycoside, D-biotin, and similar substances are commonly employed for targeting different forms of cancer [22, 23]. Several thousand publications concerning drug delivery systems illustrate their internalization through either receptor-ligand interaction within the endocytosis pathway or passively through the concept of the enhanced permeable retention (EPR) effect. These endeavors are essential from the standpoint of patient care, reducing drug misuse, and minimizing mortality.

Advertisem*nt

4. Theranostics and importance of self-immolative linker

The ongoing management of cancer in the modern era motivates the development of inventive protocols for delivering anticancer drugs, aiming to enhance the therapeutic window. In light of this, the concept of theranostics emerges in the current century. Theranostics represents a pioneering cornerstone in nanomedicine, possessing both diagnostic and therapeutic capacities that work simultaneously and complementarily. It offers the capability to provide immediate insights into real-time drug activation, distribution, and the scope of therapeutic interventions. Typically, magnetic particles, mesoporous silica, carbon, and polymer nanoparticles are used to create theranostic systems. The emergence of small molecular theranostic prodrugs in nanomedicine, which incorporate fluorophores as optical markers, has gained traction for monitoring the process of drug delivery and release. This is due to their capacity to activate fluorescence signals simultaneously with drug release. In this design approach, commonly, the reporter fluorophore and chemotherapeutic agents need to be activated simultaneously and detached from the carrier. To achieve this, one or two covalent bonds must be broken specifically within the cancerous region. The aim is to prevent the premature release of the drug into the bloodstream or normal cells. The active form of the drugs will only be attained upon encountering specific entities that are notably abundant within the cancer cells. The most sophisticated approach involves designing a theranostic prodrug that ensures seamless breakage of the chemical bond precisely at the tumor site. Figure 1 illustrates the framework for the potential activation of both the reporter and the drug. In each instance, there exists an activation or breaking point, which triggers the cleavage process. Subsequently, the self-immolative linker undergoes fragmentation through a distinct decomposition process that enables the formation of both the reporter fluorophore and the drug, allowing them to attain their active states. In the Type 1 approach, cleavage happens at the center of the linker, leading to the production of both the active drug and fluorophore through self-immolation. In the Type 2 approach, the triggering unit in the tumor-specific region activates a coordinated pathway to generate both the fluorophore and drug via the elimination strategy with the formation of unstable quinoid methide intermediates. In the Type 3 strategy, the triggering unit within the theranostic is activated upon interaction with the cancerous entity, subsequently producing the drug and fluorophore either simultaneously or stepwise within a kinetically controlled timeframe. These approaches entail a comprehensive exploration of endogenous stimuli-responsive theranostic, which is further elaborated in the following subsections.

Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect (4)

4.1 Glutathione-activated theragnostic

Glutathione (GSH) is a tripeptide composed of glutamic acid, cysteine, and glycine. Functioning alongside its oxidized form glutathione disulfide (GSSG), it serves to uphold cellular redox balance. Primarily generated in the cytosol, it predominantly remains there, safeguarding against oxidative stress by counteracting reactive oxygen species (ROS). Moreover, glutathione (GSH) plays a pivotal part in numerous cellular activities, including cell differentiation, proliferation, and apoptosis.

The concentration of GSH in cancer cells is significantly higher than that found in normal cells, with intracellular GSH levels (1–10mM) approximately 1000 times greater than those in the extracellular compartment (2–20μM). This heightened GSH concentration renders neoplastic tissues more resistant to chemotherapy [24]. Additionally, increased GSH levels in certain tumor cells are commonly linked to elevated GSH-related enzyme activity, such as γ-glutamylcysteine ligase (GCL) and γ-glutamyl-transpeptidase (GGT), along with an upregulation of GSH-transporting export pumps [25]. Undoubtedly, GSH can serve as a significant trigger for the targeted delivery of chemotherapy to the tumor microenvironment.

Within the small molecular theranostic approach, both the fluorophore and drug are linked through a spacer containing a susceptible “–S–S–” linker, which can be broken down by cellular glutathione (GSH). In addition to this responsive bis-thiol (–S–S–) linker, a cancer-targeting ligand has been integrated to enhance the selective release of therapeutics in specific cancer cells. As depicted in Figure 2, the doxorubicin linked with folate (1) and containing an –S–S– linker initially displayed inactive doxorubicin fluorescence due to an atypical photoinduced electron transfer (PET) to the folic acid [26]. After being taken up by folate receptor-positive (FR+) adenocarcinoma human alveolar basal epithelial cells (A549), theragnostic prodrug 1 exhibited red fluorescence, indicating the activation of doxorubicin. In 24hours, Dox completely translocated to the nucleus and integrated with topoisomerase II. In contrast, folate receptor-negative breast cancer cells (MCF-7) subjected to the same treatment did not exhibit any indication of doxorubicin release, as there was no observable fluorescence representing active doxorubicin Crucially, the stability of doxorubicin in plasma has enhanced, with a half-life (t1/2) of 47hours. Its efficacy in eradicating FR+ cancer cells was notably heightened, with an IC50 value of 1.27μM, surpassing that of doxorubicin alone.

Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect (5)

Another theranostic prodrug 2 [27], in combination with SN-38, a topoisomerase I inhibitor, and biotinylated rhodol, has demonstrated effective anticancer properties in biotin receptor-positive A549 cells and HeLa cells. Both of these biotin receptor-positive cell lines exhibited strong green fluorescence attributed to the production of active rhodol. Conversely, the normal NIH3T3 cell line did not display this activity, despite having sufficient glutathione. This indicates that biotin in 2 (Figure 3) plays a crucial role in the selective internalization of 2via receptor-mediated endocytosis in biotin receptor-positive cell lines. Ex-vivo data indicated that the theranostic prodrug selectively has accumulated in the tumor, resulting in the reduction of tumor volume and weight. Different cancer cell-specific ligands, anti-cancer medications, and fluorophore/imaging instruments have been employed to monitor selective chemotherapeutic interventions in both in vitro and in vivo settings, as outlined in Table 1 [28, 29, 30, 31, 32, 33, 34, 35].

Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect (6)

TheranosticsDrugsTarget ligandAbs./emission (λabs/ λem) nmIn vitro cellsEx vivo/in vivoRef.
1CPTRGD (Arg-Gly-Asp) integrin430/535U87[28]
5GemcitabinD-biotin700 (TP) /450A549[29]
1GemcitabineFolate630/700KBKB cell mice[30]
DCM-S-CPT
(PEG-PL)
CPTEPR effect465/665BCap-37BCap-37 tumor xenograft mod[31]
6GemcitabinD-biotin700/720A549[32]
1HJ-inhibitorD-biotin430/540HepG2[33]
1chlorambucil430/540HeLa[34]
TP-1SN-38PVA-biotin510/550HeLa[35]

Table 1.

Examples of GSH-stimuli responsive theranostics.

While GSH-triggered theranostics have primarily been examined, concerns about stability in blood plasma persist due to the considerable presence of thiol entities in the blood.

4.2 Hydrogen peroxide mediated theranostics

Hydrogen peroxide is a widely recognized reactive oxygen species formed from superoxide in mitochondria. It plays a critical role in cell signaling, proliferation, and maintaining redox balance. However, it is continuously produced in cancer cells (at a rate of 0.5nmol per 1×104 cells per hour) [36]. The cancer cells utilize hydrogen peroxide as a mechanism to acquire nutrients from neighboring fibroblasts through stromal induction of autophagy and mitophagy. Moreover, it leads to DNA damage, cellular metabolism, and inflammation by activating NFκB [37]. Consequently, endogenous H2O2 can serve as an excellent stimulant for the cancer cell-specific activation of theranostic prodrugs. The theranostic prodrug 3 (Figure 4) operates based on a type 2 strategy, activated in the presence of either endogenous or exogenous H2O2. It involves a two-step process to release the topoisomerase I inhibitor SN-38. The initial step, considered to be the slowest, is regarded as the rate-determining step where the boronate group transforms into ▬OH, subsequently undergoing a 1,8-elimination reaction to generate SN-38. The unstable quinone methide form of coumarin spontaneously transforms, leading to the manifestation of blue fluorescence in metastatic murine melanoma B16F10 cells and human cervical cancer cell lines (HeLa cells) [38]. It yielded promising outcomes in a murine mouse model of lung metastatic cancer, exhibiting a notably higher survival rate compared to the untreated group. Kim and colleagues noted that the combination of 5-fluorouracil (5-FU) with the self-monitoring intrinsic (mitochondrial) apoptosis marker ethidium bromide demonstrated significant antitumor activity in the A549-xenografted mice model. The theranostic prodrug resulted in a notable reduction in tumor size compared to both the control group and only the drug alone [39]. Shabat et al. observed that their prodrug, quinone cyanine 7-CPT, was activated in human glioblastoma multiform (GBM) U-87 cells in the presence of exogenous H2O2 (5 equivalents) [40]. The complete release of camptothecin (CPT) occurred within 90minutes, monitored by the emission of quinone cyanine 7 (QCy7) at 720nm. Administering the theranostic prodrug intratumorally and through intravenous tail vein injection in U-87 MG tumor-bearing mice generated a strong fluorescence signal in the tumor region, attributed to the activation of the drug.

Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect (7)

Utilizing ROS-mediated theranostic, particularly the activation of prodrugs induced by H2O2 could represent a futuristic strategy to enhance the therapeutic potential of anticancer drugs.

4.3 Hydrogen sulfide stimuli-responsive theranostic

Hydrogen sulfide, a gasotransmitter, plays a crucial role in neurotransmission. Enzymes like cystathionine γ-lyase (CSE) and cystathionine β-synthase (CBS) are overexpressed in certain cancer cells to generate endogenous H2S [41]. This compound aids in cellular bioenergetics, supporting tumor growth and proliferation, and also facilitates angiogenesis and vasorelaxation, contributing to the blood supply and nutrient provision for the tumor [42, 43]. Other than colon cancer, Bhuniya et al. noted that cervical cancer cells (HeLa cells), breast cancer cells (MDA-MB-231 cells), and prostate cancer cells (DU145 cells) generate a larger amount of H2S in the mitochondria compared to normal cells [44]. The same research group later employed a distinctive strategy to specifically decrease the mitochondrial inner membrane potential (Ѱ) in cancer cells by releasing the 2,4-dinitrophenol protonophore (Figure 5, prodrug 4) [45]. The blue emission of the coumarin fluorophore tracked the degree of protonophore activation. It was noted that prodrug 4 (Figure 5) led to elevated ROS production and ATP depletion in both colon cancer cells (HCT116 cells) and cervical cancer cells (HeLa cells), along with a decrease in the mitochondrial inner membrane potential (Ѱ). These effects selectively halted the proliferation of cancer cells (HCT116 cells and HeLa cells) while maintaining the proportional growth of normal cells (3T3L1). Another theranostic agent, TP-HS, released the topoisomerase I inhibitor SN-38 in colon cancer cells (HCT116 cells) and lung cancer cells (A549 cells), which was monitored using the rhodol fluorophore [46]. In contrast, TP-HS did not exhibit any indication of SN-38 release in normal human fibroblast cells, WI-38 cells. It demonstrated cancer cell-specific antiproliferative activity, while SN-38 resulted in nonspecific growth arrest in both normal and cancer cells. Furthermore, SN-38 led to undesired necrosis pathway cancer cell death (18%), whereas the theranostic prodrug TP-HS exclusively followed the apoptosis pathway, arresting cancer growth. The H2S-Gem theranostic prodrug exhibited dose and time-dependent labeling of cancer cells, including HeLa cells and A549 cells, while remaining inactive in normal human fibroblast cells WI38 [47]. It displayed the highest toxicity to both cancer cells (HeLa and A549) at concentrations below 5.0μM of H2S-Gem. However, it did not demonstrate any toxicity in WI38 cells even after 72hours of incubation. In this scenario, the coumarin fluorophore acted as a reporter, providing temporal information on the activation of gemcitabine. Shi and colleagues created a photo-controlled camptothecin release theranostic tailored for endogenous H2S-rich cancer cells [48]. The nanoplatform, known as NPs@BOD/CPT, was composed of borondipyrromethene (InTBOC-Cl) functioning as an H2S-triggered near-infrared (NIR) photothermal agent, with camptothecin-11 (CPT-11) enclosed within thermosensitive nanoparticles. In the absence of H2S, it did not exhibit any hyperthermic effects, and there was no leakage of CPT-11 when exposed to NIR laser. However, in the presence of 576nm NIR light, the theranostic induced significant damage to cancer cells, owing to the combined action of hyperthermia and the release of CPT-11 in the presence of H2S. In an in vivo HCT116 tumor-bearing mouse model, treatment with nano-theranostics and NIR irradiation reduced tumor size and volume after 14days.

Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect (8)

Utilizing endogenous H2S for theranostic activation in different cancer types is a distinctive strategy. It eliminates the need for a cancer-specific ligand, simplifying the synthesis of theranostic prodrugs, and making the process more straightforward and highly valuable for cancer treatment.

4.4 pH-dependent theranostics activation

The characteristic feature of cancer is an extracellular acidic environment. This arises from the production of lactic acid through anaerobic glycolysis and increased activity of the pentose pathway, resulting in the generation of carbonic acid within cancer cells. While the extracellular pHe in normal cells typically remains at 7.4, the extracellular pHe in cancer cells, on the other hand, ranges between 6.3 and 7.1. Therefore, the hydronium ion (H3O+) may serve as a potential trigger for the activation of chemotherapeutics from their theranostic prodrug systems. Zhang et al. introduced a theranostic compound called Mal-hyd-Dox, which utilized an integrin-specific Gly-Arg-Gly-Asp-Ser (GRDS)-oligopeptide as a cancer cell-specific ligand [49]. Dox was linked to the compound via an acid-sensitive hydrazone linker, and it featured a coumarin reporter. The fluorescence emitted by coumarin in Mal-hyd-Dox was initially faint; however, it became luminescent upon internalization in U87 cells within an acidic endosomal environment. The compound exhibited an IC50 value of 0.19μgmL−1, and both Dox and coumarin acted as reporters, providing red and blue channel images, respectively. In the same category, Zhang et al. developed a double FRET-based theragnostic that both caspase (Asp-Glu-Val-Asp (DEVD) peptide sequence) and pH act as stimulators for releasing doxorubicin in U87 cells [50]. The cleavage of the DEVD peptide sequence regenerated a green fluorescence based on fluorescein, demonstrating a pronounced anticancer effect (IC50=4.3×10−6M). Sessler and colleagues introduced a bimodal multifunctional theranostic conjugate 5 (as depicted in Figure 6) with T1-weighted MRI. This conjugate consisted of a paramagnetic motexafin gadolinium (MGd) texaphyrin unit connected to two doxorubicin subunits via an acid-labile hydrazone linker [51]. Initially, the fluorescence signal of doxorubicin was quenched by the strong paramagnetic signal of gadolinium ions. However, upon internalization in A549 (human lung) cancer cells and CT26 (murine colon carcinoma) cancer cells, the labile hydrazone bond encountered the acidic pH of cellular lysosomes (approximately pH4.5), resulting in the release of doxorubicin. Consequently, the release of doxorubicin was monitored using T1-weighted MRI and fluorescence imaging (Dox). This integration of MRI and optical imaging modalities allows for the visualization of tumors using MRI and the analysis of histological samples through optical imaging. Additionally, it enables the delineation of tumors via both MRI and intra-operative optical imaging.

Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect (9)

Later Wang et al. incorporated PEGylated biotin as a targeting ligand to improve the selectivity for precise anticancer activity in biotin receptor-positive human colorectal cancer cell lines (HT-29 and LS180 cells) [52]. The theranostic prodrug 6 (Figure 7) combined labile hydrazone derivatives of doxorubicin and conjugation of PEGylated biotin. The prodrug 6 was applied to colorectal cancer cell lines beforehand, resulting in a halt in the cell cycle with percentages of 69.54 and 76.76% at 12h and 24h, respectively. In contrast, colorectal cancer cells that were not treated showed a G1 phase percentage of 67.45%. On the contrary, prodrug 6 cannot release payload to receptor-negative human embryonic kidney (HEK 293) cells. Prodrug 6 readily enters cells through receptor-mediated endocytosis and is then localized in the nucleoli following the breakdown of the hydrazone bond in the lysosome. During in vivo biodistribution studies, free doxorubicin displayed notable accumulation in heart tissue, while prodrug 6 primarily accumulated in tumor tissue. Prodrug 6 exhibited a considerable tumor volume and weight loss in LS180 cells inoculated mice without causing overall body weight reduction. Conversely, mice with tumors, injected with doxorubicin, experienced significant weight loss posttreatment. The interaction between the ligand and receptor promotes increased uptake of prodrug 6 by the tumor tissues, and cellular acidosis facilitates the controlled release of the anticancer agent doxorubicin within the tumor site, thereby minimizing its adverse effects on overall health.

Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect (10)

In general, these strategies revolve concept of prodrugs, wherein established commercial drugs are repurposed as part of a novel formulation system following chemical alterations in anticancer medications. Occasionally, these modifications can impact the drug’s metabolic properties. Kamkaew et al. devised a novel pH-triggered photodynamic therapy approach using theranostic 7 (Figure 8) as its foundation [53]. In an acidic environment, it demonstrated a significant increase in reactive oxygen species generation compared to physiological pH levels (around pH7.4). Essentially, within an acidic environment, there is a decrease in the energy gap between orbitals and an enhancement in intramolecular charge transfer, promoting the formation of singlet oxygen under NIR irradiation at 850nm. Consequently, theranostic molecule 7 exhibited robust photodynamic efficacy in HepG2 hepatic carcinoma cells, while remaining inert in normal human embryonic kidney cells. Additionally, it exhibited efficacy in penetrating deep-seated tumor tissues, suggesting potential for enhanced in vivo outcomes.

Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect (11)

While the acid labile activation of theranostics demonstrated promising outcomes, a substantial portion of the payload may be released in the extracellular matrix due to its acidic nature. Consequently, this conventional strategy might not suffice as a robust approach.

4.5 β-Galactosidase stimulated theranostics

β-galactosidase exhibits notable potency as a cancer biomarker in specific cancer subtypes, including colon cancers, lung cancers, liver cancers, and ovarian cancers [54]. Bhuniya and colleagues observed that a coumarin-conjugated theranostic 8 (Figure 9) released the nucleoside drug gemcitabine to hepatic carcinoma cells (HepG2) upon encountering cellular galactosidase, as compared to cervical cancer cells and normal human foreskin (HFF-1) cells [55]. The coumarin fluorophore monitored the entire cellular uptake and drug release process. Similarly, Kolemen and Gunbas et al. utilized a β-galactosidase activatable iodo-resorufin derivative 9(Figure 9) for photodynamic therapy against cancer, showing selective activation in malignant U-87MG cells and the production of reactive oxygen species (ROS) [56]. Kim et al. demonstrated β-galactosidase stimulated release of doxorubicin from Gal-Dox (10) (Figure 9) in receptor-positive HT29 and HepG2 cells compared to the receptor-negative cervical cancer cells (HeLa cells) [57]. In an in vivo HT29-bearing mice model, the administration of Gal-Dox exhibited significant inhibition of tumor growth (53.1%) compared to free Dox treatment (34.9%). Yet, it remains unclear in nearly every instance whether alterations have occurred in the pharmaco*kinetics of the parent drug.

Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect (12)

Recently identified as a cancer biomarker, β-galactosidase is poised to find diverse applications in activating theranostic agents for targeted cancer treatments. However, till now, a limited number of theranostics have been reported. Most of the theranostics cases introduce anticancer agents with reporter fluorophore through a covalent linker, which may perturb the chemotherapeutic activity of the parent drugs, and sometimes alter metabolic ingredients which introduce unwanted toxicity. Additionally, it is crucial to focus on the design approach and gather thorough pharmaco*kinetic data on theranostic prodrugs. It is even more advantageous to consider a novel strategy centered around theranostics to circumvent reliance on currently available drugs.

4.6 Theranostics for tumor hypoxia

Unrestrained proliferation of blood vessels leads to the restriction of blood supply in the tumor area, creating a harsh hypoxic microenvironment. This condition is exacerbated by the anaerobic glycolysis in tumor tissues, triggering hypoxia through an excessive expression of hypoxia-inducible factor (HIF1α) [58]. Consequently, the HIF1α suppressor, prolyl hydroxylase, fails to regulate the expression of HIF1α. The hypoxic tumor is located at a significant distance from the closest bloodstream (≥150μm) (Figure 10), thereby preventing the diffusion of oxygen to the cancer cells, resulting in a decreased partial oxygen pressure in this zone (pO2≤20mmHg). Consequently, hypoxia diffuses heterogeneously within the solid tumor, leading to the development of metastatic tumor masses.

Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect (13)

The diminished oxygen pressure during hypoxia significantly impacts the effectiveness of current anticancer treatments. In the context of radiotherapy, the inadequate generation of reactive oxygen species in hypoxic areas often leads to radiation resistance, thereby impeding the creation of lethal damage to DNA in cancer cells. Furthermore, the hypoxia-induced HIF-1α/β factor and free oxygen radicals may stimulate the production of angiogenesis factors, counteracting the damage intended to be inflicted by radiation therapy. Likewise, the efficiency of chemotherapeutic agents is generally compromised in hypoxic tumor regions. These agents may face obstacles in reaching the hypoxic tumor area. Moreover, elevated extracellular acidosis in hypoxia plays a pivotal role in impeding the cellular uptake of chemotherapeutic agents like anthracycline analogs and others. Attaining the intended therapeutic outcomes within the hypoxic region becomes unfeasible due to the combination of reduced oxygen levels and increased distance from the nearest blood capillary. This situation represents an unfavorable prognostic and predictive factor, as it contributes to various aspects such as chemoresistance, radioresistance, angiogenesis, vasculogenesis, invasiveness, metastasis, resistance to cell death, altered metabolism, and genomic instability. In all challenging circ*mstances, different reductase enzymes are upregulated during hypoxia, effectively reducing aromatic azo (▬N〓N▬), nitro (▬NO2), and quinone moieties. Based on this inherent conversion, several theranostics have been created, wherein the cleavage of the azo bond (▬N〓N▬) or reduction of the nitro group (▬NO2) to amine (▬NH2) facilitates the self-immolative discharge of active therapeutic components into the low-oxygen area of the solid tumor. Recent advancements in hypoxia-responsive theranostics have been consolidated in Table 2.

TheranosticsActivating groupActive drugImaging modalityIn vitro cellsIn vivo/ex-vivoRef.
4▬NO2SN-38Green FLHeLa, A549HeLa cells xenograft mouse model[59]
AzP1▬N〓N▬SN-38Green FLHeLa4T1-cells inoculated xenograft murine mouse model[60]
PDU-DB-NO2▬NO2GemcitabineGreen FLMGC-803 cellsMCF-7-cell-inoculated xenograft mice[61]
1▬NO2SN-38Green FLHeLa[62]
Azo-M▬N〓N▬melphalan analogNIR FLHeLa4T1 Tumor-bearing xenograft mouse[63]
PANO(2)▬NH2OHKDAC inhibitor PanoHCT116 cellsOE21 xenografts[64]
AzCDF▬NO23,4-difluorobenzylidene curcuminGreen FLMDA-MB-231MDA-MB-231
xenografts
[65]

Table 2.

Information about various hypoxia-induced theranostic activation system.

While diverse strategic theranostics have been documented, none have yet progressed to the clinical trial stage. Further efforts are required to develop hypoxia-sensitive theranostics that may enhance clinical benefits and address existing healthcare challenges.

4.7 Light-activated theranostics

To date, we have discussed numerous endogenous stimuli-responsive theranostics that actively deliver chemotherapeutic agents to various cell types/cancers based on the presence of specific stimulants. It is important to note that these stimulants are also present in normal cells but in relatively lower quantities, thus ensuring that the therapeutic agents are selectively released solely in the tumor region cannot be guaranteed. External stimulants, such as light, have been utilized to trigger the release of therapeutics, a process commonly referred to as “photo caging,” where drugs are shielded or “caged.” UV or laser irradiation facilitates the controlled release of therapeutics in a spatially and temporally precise manner. Some critical examples of the photo trigger theranostic in a consulate form are provided in Table 3.

TheranosticsActive ingredientsIn vitro cellsIn vivo/ex-vivoRef.
OPV-LuminolLuminol & ROSHeLaHeLa cell tumor mice model[66]
10/11SN-38/CA-4MCF-7[67]
CMP-NCL-CA4 (1–5)combretastatin A-4, Pc-(L-CA4)Colon 26 cellsSC colon 26 tumors[68]
CMP-L-RhCombretastatin A-4Colon 26 cellsSC colon 26 tumors mice model[69]
1(Biotin-tagged-ONB-CC)chlorambucilMDA-MB-231 cells[70]
7,8,9CA-074 InhibitorsMDA-MB-231/MCF-10A[71]

Table 3.

Information onphoto-triggered theranostics.

The utilization of photo-triggered activation of anticancer drugs represents a unique and innovative strategy. By employing this approach, it becomes possible to activate the therapeutic agent with a higher degree of precision specifically at the intended target tumor site.

4.8 Recent cutting-edge strategies in cancer theranostics

The forefront of medical advancement includes the innovative idea of self-immolative theranostics, in which the therapeutic substance undergoes a controlled chemical reaction, causing its self-degradation under certain circ*mstances. This characteristic is frequently harnessed to prompt the release of the therapeutic payload precisely at the disease site, thereby improving its effectiveness and reducing unintended effects elsewhere. In the previously mentioned approaches, the primary focus is on delivering chemotherapeutic agents to cancer cells or tumors. However, these strategies have not yet been assessed for their effectiveness against multidrug-resistant cancers/metastasis cancer. It’s crucial to note that multidrug-resistant cancer remains one of the most lethal forms of cancer, with the highest mortality rates. With a focus on addressing multidrug-resistant cancer, Kim et al. strategically engineered prodrug 11 (depicted in Figure 11), which combines a protein phosphatase 2A (PP2A) inhibitor with a DNA damage chemotherapeutic agent linked via a GSH-responsive labile linker [72]. In this context, the protein phosphatase 2A (PP2A) inhibitor, demethyl cantharidin (DMC), inhibits PP2A activity. This inhibition leads to elevated MDM2 expression, subsequently triggering the reduction of p53-p21 mediated G1/S checkpoint arrest, thereby diminishing the DNA repair pathway. Conversely, 5-fluorouracil inhibits the growth of DNA in newly born cells. It disrupts DNA synthesis and, to a lesser extent, hinders RNA formation by integrating itself into RNA molecules, resulting in the generation of faulty RNA. Additionally, fluorouracil hampers uracil riboside phosphorylase activity, impeding preexisting uracil’s utilization in RNA synthesis. The strategic prodrug 11 is preferentially localized in the mitochondria, where triphenyl phosphonium cation drives to localize in the mitochondria. After cellular glutathione cleaves the vulnerable –S–S– bond, DMC and 5-fluorouracil are activated, ultimately disrupting the usual mitochondrial functions in cancer cells. Prodrug 11 exhibited greater anticancer efficacy in PP2A over-expressed breast cancer cell line (4T1) and colon cancer cells HCT116 compared to PP2A unexpressed cancer cell line. This heightened anticancer effect was accompanied by increased production of reactive oxygen species (ROS), resulting in DNA damage. Subsequently, mitochondrial swelling occurred, leading to the rupture of the mitochondrial outer membrane and the release of the pro-apoptotic protein cytochrome C. In the in vivo mouse model with HCT 116-inoculated mice, the combination of drugs in prodrug 11 significantly reduced tumor volume and size by three times more compared to using DMC or 5-fluorouracil alone. This exemplifies the effectiveness of combination therapy in combatting cancer.

Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect (14)

By reprogramming mitochondrial metabolism, the cancer esterase-activated prodrug 12 overcomes multidrug resistance activity, leading to delayed prodrug activation and enabling evasion of drug efflux mechanisms [73]. After esterase hydrolysis, releasing of dichloroacetate (DCA) and doxorubicin leads to p21Waf1 upregulation, reduction of PDH phosphorylation, and cleavage of caspase-3, and PARP-1 allows to show high anticancer activity in multidrug resistance MCF-7. It effectively suppressed tumor growth in the MCF/Dox xenograft mice model, with no indication of hepatotoxicity in the treated animals.

An additional theranostic prodrug, labeled as 13 [74], is triggered by various cellular reactive oxygen species (ROS) and has demonstrated its effectiveness in combating metastatic cancer. Typically, cancer cells exhibit heightened levels of multiple ROS, but a single ROS may not be adequate to activate the anticancer drug within the theranostic platform. Therefore, a carbamate-linked theranostic labeled as 13 was developed, incorporating biotin-PEGylation. Following 15days of injecting metastatic cervical cancer cell-bearing mice with doses dependent on the treatment, a remarkable inhibition of tumor growth (99%) was observed, coupled with the depletion of HIF-1α, leading to a survival period of over 45days for the treated mice.

Another formidable aspect is tumor recurrence, wherein 90% of anticancer medications fall short of providing the anticipated therapeutic effectiveness, resulting in increased mortality rates [75]. Ironically, recurrence is frequently triggered by chemotherapy as a result of the accumulation of nuclear genomic mutations throughout the treatment regimen. Antineoplastic agents that induce nuclear-DNA damage, such as alkylating agents, are prevalent chemical mutagens and have been associated with tumor recurrence. To address this ongoing challenge in cancer treatment, ciprofloxacin-conjugated 14 (MT-CFX) (Figure 11) was employed to improve mitochondrial targeting [76]. The payload release within the mitochondria triggers oxidative damage to proteins, mitochondrial DNA (mtDNA), and lipids. A significant preference for damaging mtDNA over nuclear DNA (nDNA) was observed in cancer cells. It showed anticancer activity in various cancer cells namely, MDA-MB-231(IC50: 31.31μM), SW620 (IC50: 31.82μM), DU145 (IC50: 55.51μM), A549 (IC50: 23.77μM), PC3 (IC50: 86.45μM) compared to the normal cells, BJ (IC50: 631.82μM), MCF10A (IC50: ≥1000μM). The fluorophore-linked variant of 14, known as Bo-Mt-CFX, administered via intravenous injection (0.5mmol/kg) in an MDA-MB-231 xenograft mouse model, resulted in more than a threefold reduction in both the tumor volume and size.

Hypoxia poses another challenge in overcoming multidrug resistance in tumors. Kim et al. introduced theranostic 15 (Figure 11) in conjunction with photodynamic therapy and chemotherapy to address this challenge [77]. The theranostic construct underwent reduction within the hypoxic tumor microenvironment, resulting in the liberation of a near-infrared-emissive fluorophore and an active chemotherapeutic drug. Consequently, during photodynamic therapy (PDT), theranostic 15 aided in eliminating normoxic tumor cells located in the superficial layer of the tumor. Additionally, the activatable chemotherapy facilitated the eradication of hypoxic tumor cells situated in the core of the tumors, thereby enhancing treatment efficacy for solid tumors in mice. This double-aided approach introduces a new dimension in cancer therapy, especially multidrug resistance cancer.

In this discussion, there is a notable focus on addressing multidrug resistance in cancer therapy through diverse and sophisticated strategic approaches. These methods include the activation of reactive oxygen species (ROS) and the incorporation of multidrug components. This approach integrates both the therapeutic and diagnostic components, aiming to overcome resistance mechanisms exhibited by cancer cells against multiple drugs. Through a combination of various therapeutic modalities and diagnostic techniques, this approach seeks to enhance treatment efficacy while providing insights into the resistance mechanisms at play, thereby enabling personalized and more effective cancer therapy.

Advertisem*nt

5. Conclusions and prospective outlook

In conclusion, the development and exploration of stimuli-responsive theranostics (GSH, H2O2, H2S, pH, β-galactosidase, hypoxia) have brought significant advancements to the field of cancer treatment and diagnostic capabilities. The numerous strategies and methodologies discussed herein reflect the tremendous potential of these emerging technologies. As researchers continue to delve into the intricacies of various stimuli-responsive platforms, there remains a wealth of opportunities and potential for further exploration and development in this domain. Currently, optically modulated theranostics remain primarily of academic interest. Advancing these to clinical trial phases requires generating additional data through high-throughput assays, comprehensively exploring mechanisms, and collecting pharmaco*kinetic and pharmacodynamic information.

Looking ahead, the prospective outlook for stimuli-responsive theranostics is exceedingly promising. Continued research and development in this area hold the key to addressing the existing limitations and challenges associated with traditional cancer treatment modalities. By leveraging the dynamic nature of these responsive systems, it is conceivable that refined and highly targeted therapeutic interventions can be achieved, thereby maximizing efficacy while minimizing off-target effects and potential toxicity. With a comprehensive understanding of the underlying mechanisms and a focused effort toward the development of novel and optimized therapeutic strategies, stimuli-responsive theranostics are poised to play a pivotal role in the future of personalized and precision medicine.

Advertisem*nt

Acknowledgments

SB thanks DST-SERB, India, for the research grant (CRG/2023/005905).

References

  1. 1. Hanselmann RG, Welter C. Origin of cancer: An information, energy, and matter disease. Frontiers in Cell and Developmental Biology. 2016;4:121. DOI: 10.3389/fcell.2016.00121
  2. 2. Cicenas J, Zalyte E, Bairoch A, Gaudet P. Cancers. 2018;10:63. DOI: 10.3390/cancers10030063
  3. 3. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Accounts of Chemical Research. 2011;44:1029-1038. DOI: 10.1021/ar200019c
  4. 4. Fan Z, Fu PP, Yu H, Ray PC. Theranostic nanomedicine for cancer detection and treatment. Journal of Food Drug Analysis. 2014;22:3-17
  5. 5. Sim AJ, Kaza E, Singer L, Rosenberg SA. A review of the role of MRI in diagnosis and treatment of early-stage lung cancer. Clinical and Translational Radiation Oncology. 2020;24:16-22. DOI: 10.1016/j.ctro.2020.06.002
  6. 6. Unterrainer V, Eze C, Ilhan H, Marschner S, Roengvoraphoj O, Schmidt-Hegemann NS, et al. Recent advances of PET imaging in clinical radiation oncology. Radiation Oncology. 2020;15:88. DOI: 10.1186/s13014-020-01519-1
  7. 7. Wang X, Yang M. The application of ultrasound image in cancer diagnosis. Journal of Healthcare Engineering. 2021;2021:8619251. DOI: 10.1155/2021/8619251
  8. 8. Woo Y, Chaurasiya S, O’Leary M, Han E, Fong Y. Molecular Therapy Oncolytics. 2021;23:231-238. DOI: 10.1016/j.omto.2021.06.007
  9. 9. Meyer MG, Hayenga J, Neumann T, Katdare R, Presley C, Steinhauer D, et al. The cell-CT 3D cell imaging technology platform enables the detection of lung cancer using the non-invasive LuCED sputum test. Cancer Cytopathology. 2015;123:512-523. DOI: 10.1002/cncy.21576
  10. 10. Hapuarachchige S, Artemov D. Theranostic pretargeting drug delivery and imaging platforms in cancer precision medicine. Frontiers in Oncology. 2020;10:1131. DOI: 10.3389/fonc.2020.01131
  11. 11. Li X, Kim J, Yoon J, Chen X. Cancer-associated, stimuli-driven, turn-on theranostics for multimodality imaging and therapy. Advanced Materials. 2017;29:1606857. DOI: 10.1002/adma.201606857
  12. 12. Biswas S, Rao CM. Epigenetics in cancer: Fundamentals and beyond. Pharmacology & Therapeutics. 2017;173:118-134. DOI: 10.1016/j.pharmthera.2017.02.011
  13. 13. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646-674. DOI: 10.1016/j.cell.2011.02.013
  14. 14. Boneh A, Mandla S, Tenenhouse HS. Phorbol myristate acetate activates protein kinase C, stimulates the phosphorylation of endogenous proteins and inhibits phosphate transport in mouse renal tubules. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 1989;1012(3):308-316. DOI: 10.1016/0167-4889(89)90113-4
  15. 15. Kim J, Yao F, Xiao Z, Sun Y, Ma L. MicroRNAs and metastasis: Small RNAs play big roles. Cancer and Metastasis Reviews. 2018;37:5-15. DOI: 10.1007/s10555-017-9712-y
  16. 16. Sp*rn MB, Roberts AB. Autocrine growth factors and cancer. Nature. 1985;313:745-747. DOI: 10.1038/313745a0
  17. 17. Kattan WE, Hanco*ck JF. RAS function in cancer cells: Translating membrane biology and biochemistry into new therapeutics. Biochemical Journal. 2020;477:2893-2919. DOI: 10.1042/BCJ20190839
  18. 18. Chen C, Liu TS, Zhao SC, Yang WZ, Chen ZP, Yan Y. XIAP impairs mitochondrial function during apoptosis by regulating the Bcl-2 family in renal cell carcinoma. Experimental and Therapeutic Medicine. 2018;15:4587-4593. DOI: 10.3892/etm.2018.5974
  19. 19. Safa AR. Roles of c-FLIP in apoptosis, necroptosis, and autophagy. Journal of Carcinogenesis & Mutagenesis. 2013;Suppl. 6:003. DOI: 10.4172/2157-2518.S6-003
  20. 20. Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, et al. Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives. Signal Transduction and Targeted Therapy. 2021;6:201. DOI: 10.1038/s41392-021-00572-w
  21. 21. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Moscow). 2000;65:95-106. DOI: 0006-2979/00/6501-0095
  22. 22. Kaur N, Popli P, Tiwary N, Swami R. Small molecules as cancer targeting ligands: Shifting the paradigm. Journal of Controlled Release. 2023;355:417-433. DOI: 10.1016/j.jconrel.2023.01.032
  23. 23. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nature Reviews Cancer. 2002;2(10):750-763. DOI: 10.1038/nrc903
  24. 24. Kennedy L, Sandhu JK, Harper ME, Cuperlovic-Culf M. Role of glutathione in cancer: From mechanisms to therapies. Biomolecules. 2020;10:1429. DOI: 10.3390/biom10101429
  25. 25. Váradi A, Sarkadi B. Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. BioFactors. 2003;17:103-114. DOI: 10.1002/biof.5520170111
  26. 26. Santra S, Kaittanis C, Santiesteban OJ, Perez JM. Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy. Journal of the American Chemical Society. 2011;133:16680-16688. DOI: 10.1021/ja207463b
  27. 27. Bhuniya S, Maiti S, Kim EJ, Lee H, Sessler JL, Hong KS, et al. An activatable theranostic for targeted cancer therapy and imaging. Angewandte Chemie. 2014;126(17):4558-4563
  28. 28. Lee MH, Kim JY, Han JH, Bhuniya S, Sessler JL, Kang C, et al. Direct fluorescence monitoring of the delivery and cellular uptake of a cancer-targeted RGD peptide-appended naphthalimide theragnostic prodrug. Journal of the American Chemical Society. 2012;134(30):12668-12674. DOI: 10.1021/ja303998y
  29. 29. Maiti S, Park N, Han JH, Jeon HM, Lee JH, Bhuniya S, et al. Gemcitabine–coumarin–biotin conjugates: A target-specific theranostic anticancer prodrug. Journal of the American Chemical Society. 2013;135(11):4567-4572. DOI: 10.1021/ja401350x
  30. 30. Yang Z, Lee JH, Jeon HM, Han JH, Park N, He Y, et al. Folate-based near-infrared fluorescent theranostic gemcitabine delivery. Journal of the American Chemical Society. 2013;135:11657-11662. DOI: 10.1021/ja405372k
  31. 31. Wu X, Sun X, Guo Z, Tang J, Shen Y, James TD, et al. In vivo and in situ tracking cancer chemotherapy by highly photostable NIR fluorescent theranostic prodrug. Journal of the American Chemical Society. 2014;136:3579-3588. DOI: 10.1021/ja412380j
  32. 32. Bhuniya S, Lee MH, Jeon HM, Han JH, Lee JH, Park N, et al. A fluorescence off–on reporter for real-time monitoring of gemcitabine delivery to the cancer cells. Chemical Communications. 2013;49:7141-7143. DOI: 10.1039/C3CC42653J
  33. 33. Jeon HM, Le HT, Kim TW, Kim JS. A biotin-guided fluorescent-peptide drug delivery system for cancer treatment. Chemical Communications. 2014;50:7690-7693. DOI: 10.1039/C4CC02878C
  34. 34. Wu J, Huang R, Wang C, Liu W, Wang J, Weng X, et al. Thiol-inducible direct fluorescence monitoring of drug release. Organic & Biomolecular Chemistry. 2013;11:580-585. DOI: 10.1039/c2ob26680f
  35. 35. Dutta D, Alex SM, Bobba KN, Maiti KK, Bhuniya S. New insight into a cancer theranostic probe: Efficient cell-specific delivery of SN-38 guided by biotinylated poly (vinyl alcohol). ACS Applied Materials & Interfaces. 2016;8(49):33430-33438. DOI: 10.1021/acsami.6b10580
  36. 36. Lennicke C, Rahn J, Lichtenfels R, Wessjohann LA, Seliger B. Hydrogen peroxide–production, fate, and role in redox signaling of tumor cells. Cell Communication and Signaling. 2015;13(1):1-9. DOI: 10.1186/s12964-015-0118-6
  37. 37. Lisanti MP, Martinez-Outschoorn UE, Lin Z, Pavlides S, Whitaker-Menezes D, Pestell RG, et al. Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: The seed and soil also needs "fertilizer". Cell Cycle. 2011;10(15):2440-2449. DOI: 10.4161/cc.10.15.16870
  38. 38. Kim EJ, Bhuniya S, Lee H, Kim HM, Cheong C, Maiti S, et al. An activatable prodrug for the treatment of metastatic tumors. Journal of the American Chemical Society. 2014;136:13888-13894. DOI: 10.1021/ja5077684
  39. 39. Kumar R, Han J, Lim HJ, Ren WX, Lim JY, Kim JH, et al. Mitochondrial induced and self-monitored intrinsic apoptosis by antitumor theranostic prodrug: In vivo imaging and precise cancer treatment. Journal of the American Chemical Society. 2014;136(51):17836-17843. DOI: 10.1021/ja510421q
  40. 40. Redy-Keisar O, Ferber S, Satchi-Fainaro R, Shabat D. NIR fluorogenic dye as a modular platform for prodrug assembly: Real-time in vivo monitoring of drug release. ChemMedChem. 2015;10:999-1007. DOI: 10.1002/cmdc.201500060
  41. 41. Renga B. Hydrogen sulfide generation in mammals: The molecular biology of cystathionine-β-synthase (CBS) and cystathionine-γ-lyase (CSE). Inflammation & Allergy-Drug Targets. 2011;10(2):85-91. DOI: 10.2174/187152811794776286
  42. 42. Papapetropoulos A, Pyriochou A, Altaany Z, Yang G, Marazioti A, Zhou Z, et al. Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proceedings of the National Academy of Sciences. 2009;106:21972-21977. DOI: 10.1073/pnas.0908047106
  43. 43. Szabo C, Hellmich MR. Endogenously produced hydrogen sulfide supports tumor cell growth and proliferation. Cell Cycle. 2013;12(18):2915-2916. DOI: 10.4161/cc.26064
  44. 44. Velusamy N, Binoy A, Bobba KN, Nedungadi D, Mishra N, Bhuniya S. A bioorthogonal fluorescent probe for mitochondrial hydrogen sulfide: New strategy for cancer cell labeling. Chemical Communications. 2017;53(62):8802-8805. DOI: 10.1039/c7cc05339h
  45. 45. Bobba KN, Binoy A, Koo S, Nedungadi D, Podder A, Sharma A, et al. Direct readout protonophore induced selective uncoupling and dysfunction of individual mitochondria within cancer cells. Chemical Communications. 2019;55:6429-6432. DOI: 10.1039/c9cc01483g
  46. 46. Bobba KN, Saranya G, Sujai PT, Joseph MM, Velusamy N, Podder A, et al. Endogenous H2S-assisted cancer-cell-specific activation of theranostics with emission readout. ACS Applied Bio Materials. 2019;2(3):1322-1330. DOI: 10.1021/acsabm.9b00019
  47. 47. Maiti M, Yoon SA, Cha Y, Athul KK, Bhuniya S, Lee MH. Cell-specific activation of gemcitabine by endogenous H2S stimulation and tracking through simultaneous fluorescence turn-on. Chemical Communications. 2021;57:9614-9617. DOI: 10.1039/d1cc00118c
  48. 48. Shi B, Ren N, Gu L, Xu G, Wang R, Zhu T, et al. Theranostic nanoplatform with hydrogen sulfide activatable NIR responsiveness for imaging-guided on-demand drug release. Angewandte Chemie. 2019;131:16982-16986. DOI: 10.1002/ange.201909883
  49. 49. Li SY, Liu LH, Jia HZ, Qiu WX, Rong L, Cheng H, et al. A pH-responsive prodrug for real-time drug release monitoring and targeted cancer therapy. Chemical Communications. 2014;50:11852-11855. DOI: 10.1039/C4CC05008H
  50. 50. Li SY, Liu LH, Rong L, Qiu WX, Jia HZ, Li B, et al. A dual-FRET-based versatile prodrug for real-time drug release monitoring and in situ therapeutic efficacy evaluation. Advanced Functional Materials. 2015;25(47):7317-7326. DOI: 10.1002/adfm.201503262
  51. 51. Lee MH, Kim EJ, Lee H, Park SY, Hong KS, Kim JS, et al. Acid-triggered release of doxorubicin from a hydrazone-linked Gd3+−texaphyrin conjugate. Chemical Communications. 2016;52(69):10551-10554. DOI: 10.1039/C6CC05673C
  52. 52. Yao M, Ma X, Zhang X, Shi L, Liu T, Liang X, et al. Lectin-mediated pH-sensitive doxorubicin prodrug for pre-targeted chemotherapy of colorectal cancer with enhanced efficacy and reduced side effects. Theranostics. 2019;9(3):747. DOI: 10.7150/thno.29989
  53. 53. Siriwibool S, Kaekratoke N, Chansaenpak K, Siwawannapong K, Panajapo P, Sagarik K, et al. Near-infrared fluorescent pH responsive probe for targeted photodynamic cancer therapy. Scientific Reports. 2020;10(1):1283. DOI: 10.1038/s41598-020-58239-5
  54. 54. Liu L, Mason RP. Imaging β-galactosidase activity in human tumor xenografts and transgenic mice using a chemiluminescent substrate. PLoS One. 2010;5(8):e12024. DOI: 10.1371/journal.pone.0012024
  55. 55. Maiti M, Kikuchi K, Athul KK, Kaur A, Bhuniya S. β-Galactosidase-activated theranostic for hepatic carcinoma therapy and imaging. Chemical Communications. 2022;58(44):6413-5416. DOI: 10.1039/d2cc01825j
  56. 56. Almammadov T, Elmazoglu Z, Atakan G, Kepil D, Aykent G, Kolemen S, et al. Locked and loaded: β-galactosidase activated photodynamic therapy agent enables selective imaging and targeted treatment of glioblastoma multiforme cancer cells. ACS Applied Bio Materials. 2022;5(9):4284-4293. DOI: 10.1021/acsabm.2c00484
  57. 57. Sharma A, Kim EJ, Shi H, Lee JY, Chung BG, Kim JS. Development of a theranostic prodrug for colon cancer therapy by combining ligand-targeted delivery and enzyme-stimulated activation. Biomaterials. 2018;155:145-151. DOI: 10.1016/j.biomaterials.2017.11.019
  58. 58. sem*nza GL. Expression of hypoxia-inducible factor 1: Mechanisms and consequences. Biochemical Pharmacology. 2000;59(1):47-53. DOI: 10.1016/s0006-2952(99)00292-0
  59. 59. Kumar R, Kim EJ, Han J, Lee H, Shin WS, Kim HM, et al. Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor. Biomaterials. 2016;104:119-128. DOI: 10.1016/j.biomaterials.2016.07.010
  60. 60. Zhou Y, Maiti M, Sharma A, Won M, Yu L, Miao LX, et al. Azo-based small molecular hypoxia responsive theranostic for tumor-specific imaging and therapy. Journal of Controlled Release. 2018;288:14-22. DOI: 10.1016/j.jconrel.2018.08.036
  61. 61. Liu W, Liu H, Peng X, Zhou G, Liu D, Li S, et al. Hypoxia-activated anticancer prodrug for bioimaging, tracking drug release, and anticancer application. Bioconjugate Chemistry. 2018;29(10):3332-3343. DOI: 10.1021/acs.bioconjchem.8b00511
  62. 62. Koo S, Bobba KN, Cho MY, Park HS, Won M, Velusamy N, et al. Molecular theranostic agent with programmed activation for hypoxic tumors. ACS Applied Bio Materials. 2019;2(10):4648-4655. DOI: 10.1021/acsabm.9b00722
  63. 63. Zhao YQ , Biswas S, Chen Q , Jia M, Zhou Y, Bhuniya S. Direct readout hypoxia tumor suppression in vivo through NIR-theranostic activation. ACS Applied Bio Materials. 2021;4(7):5686-5694. DOI: 10.1021/acsabm.1c00467
  64. 64. Ho TC, Chan AH, Ganesan A. Thirty years of HDAC inhibitors: 2020 insight and hindsight. Journal of Medicinal Chemistry. 2020;63(21):12460-12484. DOI: 10.1021/acs.jmedchem.0c00830
  65. 65. Kim JH, Verwilst P, Won M, Lee J, Sessler JL, Han J, et al. A small molecule strategy for targeting cancer stem cells in hypoxic microenvironments and preventing tumorigenesis. Journal of the American Chemical Society. 2021;143(35):14115-14124. DOI: 10.1021/jacs.1c03875
  66. 66. Yuan H, Chong H, Wang B, Zhu C, Liu L, Yang Q , et al. Chemical molecule-induced light-activated system for anticancer and antifungal activities. Journal of the American Chemical Society. 2012;134(32):13184-13187. DOI: 10.1021/ja304986t
  67. 67. Hossion AM, Bio M, Nkepang G, Awuah SG, You Y. Visible light-controlled release of anticancer drug through double activation of prodrug. ACS Medicinal Chemistry Letters. 2013;4(1):124-127. DOI: 10.1021/ml3003617
  68. 68. Bio M, Rajaputra P, Nkepang G, Awuah SG, Hossion AM, You Y. Site-specific and far-red-light-activatable prodrug of combretastatin A-4 using photo-unclick chemistry. Journal of Medicinal Chemistry. 2013;56(10):3936-3942. DOI: 0.1021/jm400139w
  69. 69. Nkepang G, Bio M, Rajaputra P, Awuah SG, You Y. Folate receptor-mediated enhanced and specific delivery of far-red light-activatable prodrugs of combretastatin A-4 to FR-positive tumor. Bioconjugate Chemistry. 2014;25(12):2175-2188. DOI: 10.1021/bc500376j
  70. 70. Karthik S, Kumar BP, Gangopadhyay M, Mandal M, Singh NP. A targeted, image-guided and dually locked photoresponsive drug delivery system. Journal of Materials Chemistry B. 2015;3(5):728-732. DOI: 10.1039/c4tb01583e
  71. 71. Toupin NP, Arora K, Shrestha P, Peterson JA, Fischer LJ, Rajagurubandara E, et al. BODIPY-caged photoactivated inhibitors of cathepsin B flip the light switch on cancer cell apoptosis. ACS Chemical Biology. 2019;14(12):2833-2840. DOI: 10.1021/acschembio.9b00711
  72. 72. Jangili P, Kong N, Kim JH, Zhou J, Liu H, Zhang X, et al. DNA-damage-response-targeting mitochondria-activated multifunctional prodrug strategy for self-defensive tumor therapy. Angewandte Chemie International Edition. 2022;61(16):e202117075. DOI: /10.1002/anie.202117075
  73. 73. Sharma A, Lee MG, Shi H, Won M, Arambula JF, Sessler JL, et al. Overcoming drug resistance by targeting cancer bioenergetics with an activatable prodrug. Chem. 2018;4(10):2370-2383. DOI: 10.1016/j.chempr.2018.08.002
  74. 74. Liu L, Liu F, Liu D, Yuan W, Zhang M, Wei P, et al. A smart theranostic prodrug system activated by reactive oxygen species for regional chemotherapy of metastatic cancer. Angewandte Chemie International Edition. 2022;61:e202116807. DOI: 10.1002/anie.202116807
  75. 75. Mehlen P, Puisieux A. Metastasis: A question of life or death. Nature Reviews Cancer. 2006;6(6):449-458
  76. 76. Sunwoo K, Won M, Ko KP, Choi M, Arambula JF, Chi SG, et al. Mitochondrial relocation of a common synthetic antibiotic: A non-genotoxic approach to cancer therapy. Chem. 2020;6(6):1408-1419. DOI: 10.1016/j.chempr.2020.03.004
  77. 77. Xiong J, Wang P, Son S, Zhong C, Zhang F, Mao Z, et al. Engineering a theranostic platform for synergistic hypoxia-responsive photodynamic therapy and chemotherapy. Matter. 2022;5(5):1502-1519. DOI: 10.1016/j.matt.2022.02.019

Written By

Shayeri Biswas and Sankarprasad Bhuniya

Reviewed: 20 May 2024 Published: 08 July 2024

© 2024 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect (2024)

References

Top Articles
Latest Posts
Article information

Author: Amb. Frankie Simonis

Last Updated:

Views: 6221

Rating: 4.6 / 5 (56 voted)

Reviews: 95% of readers found this page helpful

Author information

Name: Amb. Frankie Simonis

Birthday: 1998-02-19

Address: 64841 Delmar Isle, North Wiley, OR 74073

Phone: +17844167847676

Job: Forward IT Agent

Hobby: LARPing, Kitesurfing, Sewing, Digital arts, Sand art, Gardening, Dance

Introduction: My name is Amb. Frankie Simonis, I am a hilarious, enchanting, energetic, cooperative, innocent, cute, joyous person who loves writing and wants to share my knowledge and understanding with you.